BMS-986506 / BMS, Evotec - LARVOL DELTA

A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) (clinicaltrials.gov) - P1 | N=281 | Recruiting | Sponsor: Bristol-Myers Squibb | N=125 ➔ 281

Enrollment change • First-in-human • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation (Evotec Press Release) - "Dosing of first patient initiates Phase 1 clinical evaluation of BMS-986506 for the treatment of advanced clear cell renal cell carcinoma, the most common form of kidney cancer."

Financing • Trial status • Clear Cell Renal Cell Carcinoma

CA242-0001: A Phase 1/1b First-in-Human Study of BMS-986506 in ccRCC (clinicaltrialsregister.eu) - P1 | N=48 | Not yet recruiting | Sponsor: Bristol-Myers Squibb Services Unlimited Company

First-in-human • New P1 trial • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) (clinicaltrials.gov) - P1 | N=125 | Recruiting | Sponsor: Bristol-Myers Squibb | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) (clinicaltrials.gov) - P1 | N=125 | Not yet recruiting | Sponsor: Bristol-Myers Squibb

First-in-human • New P1 trial • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor